Literature DB >> 11090082

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia.

A Venditti1, F Buccisano, G Del Poeta, L Maurillo, A Tamburini, C Cox, A Battaglia, G Catalano, B Del Moro, L Cudillo, M Postorino, M Masi, S Amadori.   

Abstract

We used flow cytometry to quantify minimal residual disease (MRD) in 56 patients with acute myeloid leukemia (AML) expressing a leukemia-associated phenotype. Thirty-four patients aged 18 to 60 years were entered into the AML-10 protocol (induction, consolidation, and autologous stem-cell transplantation [ASCT]), whereas 22 patients older than 60 years received the AML-13 protocol (induction, consolidation, and consolidation II). After induction, the level of MRD that was best associated with treatment outcome was 4.5 x 10(-4) residual leukemic cells. However, the outcome in patients with at least 4.5 x 10(-4) cells (n = 26) was not significantly different from that in patients with fewer leukemic cells (n = 30); there were 15 (58%) relapses in the first group and 12 (40%) relapses in the second. After consolidation, the most predictive MRD cutoff value was 3.5 x 10(-4) cells: 22 patients had an MRD level of 3.5 x 10(-4) cells or higher and 17 (77%) of these patients had relapse, compared with 5 of 29 patients (17%) with lower MRD levels (P <.001). An MRD level of 3.5 x 10(-4) cells or higher after consolidation was significantly correlated with poor or intermediate-risk cytogenetic findings, a multidrug resistance 1 (MDR1) phenotype, short duration of overall survival, and short duration of relapse-free survival (P =.014,.031,.00022, and.00014, respectively). In multivariate analysis, this MRD status was significantly associated with a high frequency of relapse (P <.001) and a short duration of overall (P =.025) and relapse-free survival (P =.007). ASCT did not alter the prognostic effect of high MRD levels after consolidation: the relapse rate after transplantation was 70%. Thus, we found that an MRD level of 3.5 x 10(-4) cells or higher at the end of consolidation strongly predicts relapse and is significantly associated with an MDR1 phenotype and intermediate or unfavorable cytogenetic findings. (Blood. 2000;96:3948-3952)

Entities:  

Mesh:

Year:  2000        PMID: 11090082

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  53 in total

Review 1.  X-linked clonality testing: interpretation and limitations.

Authors:  George L Chen; Josef T Prchal
Journal:  Blood       Date:  2007-04-13       Impact factor: 22.113

2.  Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia.

Authors:  Roland B Walter; Ted A Gooley; Brent L Wood; Filippo Milano; Min Fang; Mohamed L Sorror; Elihu H Estey; Alexander I Salter; Emily Lansverk; Jason W Chien; Ajay K Gopal; Frederick R Appelbaum; John M Pagel
Journal:  J Clin Oncol       Date:  2011-01-31       Impact factor: 44.544

3.  Correlation of minimal residual disease cell frequency with molecular genotype in patients with acute myeloid leukemia.

Authors:  Corine J Hess; Nicole Feller; Fedor Denkers; Angèle Kelder; Pauline A Merle; Michael C Heinrich; Amy Harlow; Johannes Berkhof; Gert J Ossenkoppele; Quinten Waisfisz; Gerrit J Schuurhuis
Journal:  Haematologica       Date:  2008-11-27       Impact factor: 9.941

Review 4.  Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Authors:  Mary-Elizabeth Percival; Catherine Lai; Elihu Estey; Christopher S Hourigan
Journal:  Blood Rev       Date:  2017-02-02       Impact factor: 8.250

Review 5.  Minimal residual disease in acute myelogenous leukemia.

Authors:  N M Cruz; N Mencia-Trinchant; D C Hassane; M L Guzman
Journal:  Int J Lab Hematol       Date:  2017-05       Impact factor: 2.877

Review 6.  Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future.

Authors:  J M Jaso; S A Wang; J L Jorgensen; P Lin
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

Review 7.  Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials.

Authors:  Daniel A Pollyea; Jonathan A Gutman; Lia Gore; Clayton A Smith; Craig T Jordan
Journal:  Haematologica       Date:  2014-08       Impact factor: 9.941

Review 8.  Detection of minimal residual disease in acute myeloid leukemia.

Authors:  Maria R Baer
Journal:  Curr Oncol Rep       Date:  2002-09       Impact factor: 5.075

9.  Universal monitoring of minimal residual disease in acute myeloid leukemia.

Authors:  Elaine Coustan-Smith; Guangchun Song; Sheila Shurtleff; Allen Eng-Juh Yeoh; Wee Joo Chng; Siew Peng Chen; Jeffrey E Rubnitz; Ching-Hon Pui; James R Downing; Dario Campana
Journal:  JCI Insight       Date:  2018-05-03

Review 10.  Minimal residual disease quantitation in acute myeloid leukemia.

Authors:  David Shook; Elaine Coustan-Smith; Raul C Ribeiro; Jeffrey E Rubnitz; Dario Campana
Journal:  Clin Lymphoma Myeloma       Date:  2009
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.